Alnylam Pharmaceuticals Inc

ALNY remains in a Stage 4 decline yet qualifies for mean-reversion participation. Medium-term bias is set to Bullish on permission of a lower valuation bound and demand zone around multi-year lows. Short-term conditions remain neutral, with extreme oversold readings and price trading below declining EMAs. Execution should be deferred into stabilization and a reclaim of EMAs within the demand zone, as the active Support Failure pattern underlines continued downside risk without confirmation.

• ↑Q1 net revenue exceeded $1B, up 121% YoY; TTR franchise $910M (+153%).
• ↑Pipeline set to expand from 25 to over 40 trials, including Down syndrome–associated Alzheimer’s.
• ↓Earnings yield is negative, highlighting overvaluation concerns.